Follow us...

 

Search News Archives

Monthly Newsletter

 

Lab Bulletin May Newsletter

view the latest issue

Subscribe

News Channels

 

New Laboratory Products

 

Lab News

 

Microscopy & Image Analysis

 

Separation Science

 

Research & Case Studies

 

Literature

 

Videos

 

Events | Webinars

 

 

 

Conferences | Events

New Paper from WuXi AppTec on Shortening Timelines for Bioprocessing of Protein-Based Therapeutics

publication date: Apr 5, 2016
 | 
author/source: Sartorius Group

Sartorius Stedim Biotech (SSB) today announced a new paper entitled, ‘Shortening Timelines for Upstream Bioprocessing of Protein-based Therapeutics’ has been published in the journal, BioPharma Asia.

sartoriusThe paper details how scientists at leading Asian pharmaceutical company, WuXi AppTec are using the ambr® 15 automated micro bioreactor system to mimic bench-top and production scale bioreactors, producing comparable results with cell growth, cell metabolism and protein production, including similar protein titre to BIOSTAT® STR single-use bioreactors.

In the article, one case study describes how WuXi AppTec scientists have applied the ambr 15 system to prove similar cell growth and productivity as 1L and 3L bioreactors, with similar pH and pCO2 profiles using three different monoclonal antibody (mAb) expressing Chinese Hamster Ovary (CHO) cell lines.

The paper also details another WuXi AppTec case study using a mAb-expressing CHO cell line in a fed-batch process in ambr 15 micro scale bioreactors, a 7L glass bioreactor, a 10L single-use bioreactor and a 200L single-use BIOSTAT® STR bioreactor (SSB). The results showed that the growth profiles from the ambr 15, bench-top and production scale single-use bioreactors also had good comparability.

The success of the ambr 15 as a bioreactor mimic in these studies is due to a combination of pH & DO control, culture stirring by an impeller and gas supply by sparging, just as in bench-top and manufacturing scale bioreactors. It is these features which allow scientists at WuXi AppTec to move towards replacing their traditional shake flasks and bench top bioreactors with ambr 15, to increase scalability of early stage results and accelerating their bioprocessing workflow. 

Dr Barney Zoro, ambr 15 Product Manager, at SSB commented: “The large dose volume needed to achieve clinical efficacy and extensive production and purification steps involved, means that manufacturing costs of biologics can be high. These factors are driving the search for methods and systems to reduce the cost of goods (COGs) of producing biologics.”

Dr Zoro added: “This new paper shows how a forward thinking pharma company can reduce the COGs of biologics through an increase in upstream cell culture productivity. By using an automated micro bioreactor system WuXi AppTec’s scientists have demonstrated that bioprocess optimisation no longer needs to be limited by availability of bench-top bioreactors, operator time or facility infrastructure and this could in future contribute to reducing their development timelines and the manufacturing costs of their protein-based therapies.”


more about sartorius


more news from sartorius


 


If you have not logged into the website then please enter your details below.



 

 

Popular this Month...

Our Top 10 most popular articles this month

 

Today's Picks...

 

 


 

Looking for a Supplier?

Search by company or by product

 


Company Name:

Product:


 

 

Please note Lab Bulletin does not sell, supply any of the products featured on this website. If you have an enquiry, please use the contact form below the article or company profile and we will send your request to the supplier so that they can contact you directly.

Lab Bulletin is published by newleaf marketing communications ltd

 


Promotions

 

Media Partners